Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of common stock, warrants and rights. Under a prospectus supplement the company established an at-the-market (ATM) program with H.C. Wainwright to sell up to $32,500,000 of common stock. The supplement estimates up to 11,363,636 shares based on a $2.86 per-share price and states Wainwright will receive a 3.0% selling commission.
The prospectus describes the NAVIGATE Phase 2b/3 study results for belapectin, noting a 49.3% reduction in varices in the per-protocol population (n=287) and a 68.1% reduction (p=0.02) in the U.S. completer subgroup. Shares outstanding are listed as 65,827,448 as of March 16, 2026 (and 65,201,995 as of December 31, 2025 in dilution examples).
Galectin Therapeutics Inc. reported full-year 2025 results showing a narrower loss while advancing its belapectin program for MASH cirrhosis and portal hypertension. Net loss was $30.8 million for 2025, improved from $47.0 million in 2024, as total operating expenses fell to $20.1 million from $42.4 million on sharply lower research and development spending.
Basic and diluted net loss per share improved to $0.48 from $0.76, with 63.9 million shares used in the 2025 per-share calculation. Cash and cash equivalents were $17.7 million at December 31, 2025, up from $15.1 million a year earlier, and the company highlighted an additional $10 million line of credit from its chairman, extending projected cash runway through April 2027.
Management emphasized encouraging biomarker and clinical signals from the NAVIGATE study supporting belapectin’s potential antifibrotic and disease‑modifying activity in MASH cirrhosis and portal hypertension. Multiple NAVIGATE abstracts, including an oral presentation, were accepted for the EASL Congress, and the company expects an FDA meeting in the second quarter of 2026 to discuss next steps for belapectin.
Galectin Therapeutics Inc. files its annual report describing progress and setbacks in developing belapectin, a galectin-3 inhibitor for MASH cirrhosis and cancer. The NAVIGATE Phase 2b/3 trial reduced varices in key subgroups but missed its composite primary endpoint, leaving future Phase 3 plans uncertain. The company reported an accumulated deficit of $431 million, research and development spending of $14.3 million in 2025, and year-end unrestricted cash of $17.7 million plus a $10 million credit line from its chairman, which together are expected to fund operations only through April 2027. Galectin remains pre-revenue, depends heavily on a single financier, and disclosed a material weakness in internal control over financial reporting, while continuing to emphasize belapectin’s safety profile and biomarker improvements in advanced MASH cirrhosis.
Galectin Therapeutics Inc director Henry Brem received a grant of stock options. The award covers 60,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $3.1600 per share, reported as a direct holding.
The options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. They vest 100% on December 31, 2026 and are scheduled to expire on March 12, 2036. Following this grant, Brem holds 60,000 stock options linked to Galectin common stock.
Galectin Therapeutics Inc. director Henry Brem filed an initial ownership report on Form 3 showing no common stock holdings. The filing indicates that, as of the reporting date, he is a director of the company but does not beneficially own any shares of common stock directly.
Galectin Therapeutics Inc. appointed Henry Brem, M.D. as an independent member of its Board of Directors, effective March 12, 2026. The company states he was not appointed under any arrangement with another person and has no related-party transactions requiring disclosure under Regulation S-K Item 404(a).
Dr. Brem is a renowned neurosurgeon-scientist and translational medicine leader, serving as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. He helped develop image-guided neurosurgical techniques and localized drug delivery systems such as Gliadel wafers, has published more than 416 peer-reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades.
The Board believes his extensive medical, clinical development, and leadership background will support Galectin’s strategy as it advances its galectin-3 inhibitor belapectin for patients with MASH cirrhosis, portal hypertension, and certain cancers. He will receive compensation consistent with the company’s standard non-employee director program.
Galectin Therapeutics director Eldred Kary reported a small open‑market purchase of company stock. On 02/06/2026, Kary bought 300 shares of common stock at $2.70 per share, bringing his direct holdings to 65,682 shares.
The filing also lists 2,425 shares held as custodian for a minor child under the Uniform Transfers to Minors Act and 2,000 shares held in a special needs trust where he serves as trustee. Kary disclaims beneficial ownership of these indirect holdings.
Galectin Therapeutics Inc. reported an amended insider transaction for its President, CEO and director, Jack W. Callicutt. On January 16, 2026, he was granted a stock option to buy 91,000 shares of common stock at an exercise price of $3.04 per share under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The option vests in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expires on January 16, 2036. Following this grant, Callicutt directly holds 91,000 derivative securities in the form of these options. This Form 4/A corrects the originally filed number of options previously reported on January 21, 2026.
Galectin Therapeutics director Carson Benjamin Sr reported an award of stock options under the company’s 2019 Omnibus Equity Incentive Plan. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, recorded at a price of $0 for the grant itself. These options give the right to buy Galectin Therapeutics common stock and are held as direct ownership.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date and remain outstanding until their expiration on January 16, 2036. Following this grant, Benjamin beneficially owns 60,000 derivative securities in the form of these stock options.
Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.
The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.